Prosecution Insights
Last updated: August 17, 2026
Application No. 19/042,038

SOYBEAN VARIETY

Non-Final OA §101§112
Filed
Jan 31, 2025
Priority
Feb 05, 2024 — provisional 63/549,638
Examiner
BYRNES, DAVID R
Art Unit
Tech Center
Assignee
Syngenta AG
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
187 granted / 240 resolved
+17.9% vs TC avg
Strong +22% interview lift
Without
With
+22.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
31 currently pending
Career history
278
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
22.3%
-17.7% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
46.8%
+6.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 240 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims Claims 1-20 are examined. Election/Restrictions Applicant’s election of species EC2141788 in the reply filed on 6/24/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the requirement for election of species, the election has been treated as an election without traverse (MPEP § 818.01(a)). Duty of Disclosure Applicant is reminded of their “Duty of Disclosure, Candor, and Good Faith” (see 37 C.F.R. § 1.56 and MPEP § 2001). Information that would be considered material to patentability includes: 1) any progeny, siblings, half-siblings, or other closely genetically related plants that are either co-pending applications or previously published or publicly disclosed, 2) if backcrossing was used in the breeding history, then the recurrent parent should be disclosed along with any publications or public disclosures of the recurrent parent, and what events/loci/transgenes/traits were donated from the non-recurrent parent along with any publications or public disclosures of the events/loci/transgenes/traits or of the donor parent line itself, 3) if the parental varieties were developed via backcrossing this should be disclosed along with the grandparents, including which grandparent was the recurrent parent along with any publications or public disclosures of the recurrent parent and what events/loci/transgenes/traits were donated from the non-recurrent parent, 4) any alternative designations, experimental names, tradenames, etc. for the instant plant, parent plants, and grandparent plants (if backcrossing was used for the parents) should be disclosed. All of this information is material to patentability. If, for example, one of the parent plants is published but with a different name/designation, then the publication should be included in the IDS along with an explanation that the different name/designation is a synonym and how this plant is related to the instantly claimed plant. APPLICANT IS ADVISED TO INFORM THE EXAMINER IF ANY OF THE SOYBEAN VARIETIES THAT HAVE NOT BEEN ELECTED FROM CLAIM 1 ARE CLOSELY RELATED GENETICALLY TO EC2141788, THE ELECTED VARIETY UNDER EXAMINATION (e.g., BACKCROSSING IN THEIR BREEDING HISTORY UTILIZING THE SAME RECURRENT PARENT, OR SIBLINGS FROM THE SAME BREEDING PROGRAM, ETC.). Specification The disclosure is objected to because of the following informalities: there are blank lines where there should be an accession number, date of deposit, and date of viability testing (Spec, page 45). It is noted that it appears the deposit number for the elected variety, EC2141788, is present: 202312089. The abstract of the disclosure is objected to because it does not indicate that which is new in the art to which the invention pertains. Correction is required. See MPEP § 608.01(b). The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The specification provides a value of “WLBBI” for “Plant Morphological” in Table 17 on Page 65. Then in the description of that figure states that the traits are listed in the following order: Flower, Pubescence, Pod color and Hilum. It is not clear if the value for pod color is missing or is “B” for brown. If it is the latter, it would appear that the value for hilum is “I”, which is not defined by Applicant. For the purposes of examination, the morphological traits are interpreted as white flower, light brown pubescence, no value for pod color and hilum black. Table 17 or its description should be corrected to clarify this. Appropriate correction is required. Claim Interpretation Claim 3 is interpreted to encompass a plant that was directly transformed rather than a plant which had a transgene introgressed via crossing and/or backcrossing. Claim 6 recites “… sufficient inbreeding to produce an inbred soybean plant…” and one of ordinary skill in the art would understand this means ending with multiple rounds of selfing and/or sibling crossing to fix the genetics. Claim 14 recites “single locus conversion” and claim 15 recites “single locus”. This is interpreted to mean that there is only one locus converted relative to the deposited seeds of the line. Claim Objections Claims 1, 6, and 12 are objected to because of the following informalities: Claim 1 recites the acronym “PTA” without first defining it. Any acronyms should have the full name written out with the acronym in parentheses the first time it appears. Claim 6 recites “… crossing … … with itself …” multiple times, and this is technically incorrect. Crossing involves using pollen from one plant and using it to pollinate the female flower of a different plant; see, for example claim 14 part (c). This is in contrast to self-pollination. Claim 12 includes “a site-specific recombination site” in a Markush grouping of traits, and this is not a trait. Applicant is advised to insert - - the transgene or locus comprises a site-specific recombination site or wherein - - between “claim 11, wherein” and “the desired trait”; and delete “a site-specific recombination site” from the list of traits. Appropriate correction is required. Improper Markush Grouping Claims 1, 6, 11, 13, 14, 15 and 18 are rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. The members of the improper Markush grouping do not share a substantial feature and/or a common use that flows from the substantial structural feature for the following reasons: The members of the group appear to be patentably distinct soybean varieties with different characteristics and different genetic lineages. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1) (emphasis provided). Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 18-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claimed invention is directed to a judicial exception (abstract idea) without significantly more. Claims 18-19 recite a method comprising isolating nucleic acids from a plant, a plant part, or a seed of soybean variety EC2141788, analyzing said nucleic acids to produce data, and recording the data (to a computer readable medium, claim 19). According to MPEP 2106, the claim must not be directed to a judicial exception unless the claim as a whole includes additional limitations amounting to significantly more than the exception. The judicial exceptions (also called "judicially recognized exceptions" or simply "exceptions") are subject matter that the courts have found to be outside of, or exceptions to, the four statutory categories of invention, and are limited to abstract ideas, laws of nature and natural phenomena. According to MPEP 2106.04, judicially recognized exceptions have been described using various other terms, including "physical phenomena," "products of nature," "scientific principles," "systems that depend on human intelligence alone," "disembodied concepts," "mental processes," and "disembodied mathematical algorithms and formulas." In this case, analyzing said nucleic acids to produce data, and recording the data encompass scientific principles, mental processes, and/or disembodied mathematical algorithms and formulas, which are abstract ideas. Isolating nucleic acid is a lab step. Analyzing said nucleic acids may comprise lab tests (part of analyzing). However, such isolating and lab test are routine methods, and do not constitute significantly more to the abstract idea. Claim 20 merely recites using the data but does not recite how to use the data “for crossing, selection or advancement decision”. In addition, crossing or selecting is not recited as a step, only as a intend purpose. Thus, the claim is directed to abstract ideas. Hence, as a whole, the claims are directed to abstract ideas without significantly more, which are deemed to be a juridical exception. Therefore, claims are directed to judicial exceptions without significantly more, and are rejected under 35 U.S.C. 101. Claim Rejections - 35 USC § 112 Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1, and ALL CLAIMS DEPENDENT THEREON, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 is indefinite in its recitation of “ATCC Accession Number” in combination with blanks, because the accession numbers are missing. Amending the claim to recite the accession numbers, or the assurance that the claim will be so amended, would overcome the rejection. Claims 1, 6, 11, 13, 14, 15 and 18, and ALL CLAIMS DEPENDENT THEREON, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims 1, 6, 11, 13, 14, 15 and 18, are indefinite in the recitation of “EC2120882, EC2120769, EC2120992, EC2121886, EC2122763, EC2122906, EC2140839, EC2140504, EC2141788, or EC2141422”, given that a name does not clearly identify the claimed soybean varieties and seed, and does not set forth the metes and bounds of the claimed invention. Since the names EC2120882, EC2120769, EC2120992, EC2121886, EC2122763, EC2122906, EC2140839, EC2140504, EC2141788, or EC2141422 are not known in the art, the use of the names does not carry art recognized limitations as to the specific characteristics or essential characteristics which are associated with these denominations. In addition, the names appear to be arbitrary and the specific characteristics associated therewith could be modified. Amending the independent claims to recite the accession number, or the assurance that the claims will be so amended, would overcome the rejection. Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 13 is indefinite because it is unclear which of the physiological and morphological characteristics of soybean variety EC2120882, EC2120769, EC2120992, EC2121886, EC2122763, EC2122906, EC2140839, EC2140504, EC2141788, or EC2141422 are altered by at least one transgene or locus conferring a desired trait and which are not, because the specification does not indicate which physiological and morphological characteristics of soybean variety EC2120882, EC2120769, EC2120992, EC2121886, EC2122763, EC2122906, EC2140839, EC2140504, EC2141788, or EC2141422 could be subject to alteration. Claim 15 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 15 is indefinite because it is unclear which of the physiological and morphological characteristics of the elected soybean variety are essential and which are not, because the specification does not define “essentially all”. Claim 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 16 is indefinite because it is unclear whether the commodity plant product produced by the method is intended to be limited to protein concentrate, protein isolate, soybean hulls, meal, flour, or oil, because “comprising” recited before the list of products is open claim language, and thus nonlimiting. Written Description Claims 13 and 17 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 13 and 17 are broadly drawn to a genus of plants produced by the method of claim 11, and a seed that produces the plant of claim 13. Claim 11 recites introducing at least one transgene or locus conferring the desired trait into the soybean plant EC2141788. Please note claim 11 does not recite introducing a single transgene or locus. As it is claimed, “at least one transgene or locus,” it encompasses an unlimited number of transgenes or locus conversions. The specification describes some morphological characteristics of EC2141788 (pages 94-97, Tables 25-26). EC2141788 comprises only specific transgenes (MON 89788, A5547-127, MON87708, Rag1_S and Rps1c) which confer herbicide tolerance and phytophthora resistance and not any other transgenes or locus conversions. However, the specification does not provide any example of EC2141788 further comprising a transgene or locus conversion, not to mention the common structure feature of the genus of plants or seeds. Li et al (Li, Plant Biotechnology Journal 20.6 (2022): 1110-1121) provides that an introduced locus conversion comprising a transgene (ST1 locus) dramatically and significantly changes many physiological and morphological characteristics/traits of the original soybean variety (GR8836), and changed oil content (p1110, Summary; p1112-1113, Results). Thus, unlimited number of transgene or loci would dramatically and significantly change many physiological and morphological characteristics/traits of the original soybean variety. In another word, the plant produced by the method of claim 11 would not maintain all of physiological and morphological characteristics of EC2141788. The structure of EC2141788, and the morphological and physiological characteristics that are connected to the structure does not comprise any further transgenes, thus does not describe the common structure feature of the genus of converted seeds, plants, plant parts, and does not represent genus of converted seeds, plants, or plant parts. Therefore, the application has not met either of the two elements of the written description requirement as set forth in the court' s decision in Eli Lilly, and has not shown her/his possession of the claimed genus at the time of the application. Amending claim 11 to recite a single transgene or locus conversion would overcome the rejection. With respect to claim 17, Applicant claims a soybean seed that produces the plant of claim 13. Applicant describes soybean cultivar EC2141788 in Tables 17 and 18 on pages 65-66. Applicant does not describe the genus of soybean plants derived from soybean cultivar EC2141788 encompassing an unlimited number of transgenes or locus conversions. See Vas-Cath Inc. v. Mahurkar 1991 (CA FC) 19 USPQ2d 1111, 1115, which teaches that the purpose of the written description is for the purpose of warning an innocent purchaser, or other person using a machine, of his infringement of the patent; and at the same time, of taking from the inventor the means of practicing upon the credulity or the fears of other persons, by pretending that his invention is more than what it really is, or different from its ostensible objects, that the patentee is required to distinguish his invention in his specification. In this case, there is no way that a practitioner would be able to determine if any particular soybean plant is infringing the instant claims, and therefore, the public has not been put on notice with a sufficient description of the claimed invention. Claims 13 and 17 are “reach through” claims in which the Applicant has described a starting material and at least one method step, but has not described the resulting product; and wherein the genus of products that can be produced by the recited method steps and materials is so large that one of skill in the art is not able to envision the members of the genus. (See Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 920-23, 69 USPQ2d 1886, 1890-93 (Fed. Cir. 2004)). Accordingly, the specification fails to provide adequate written description to support the genus of soybean plants produced by introducing at least one mutation into soybean cultivar EC2141788. Missing Breeding History The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1-20, as they read on the elected species, are drawn to a plant, plant part, or seed of soybean variety EC2141788, and to methods of making and using the plants, plant parts, seeds, and products. The instant Specification fails to satisfy the written description requirement of 35 U.S. Code § 112(a) because it does not provide a description sufficient to conduct an examination, including search of the prior art, nor does it provide enough description to be sufficient to aid in the resolution of questions of infringement. MPEP 2163 (I) states “The written description of the deposited material needs to be as complete as possible because the examination for patentability proceeds solely on the basis of the written description. See, e.g., In re Lundak, 773 F.2d 1216, 227 USPQ 90 (Fed. Cir. 1985); see also 54 Fed. Reg. at 34,880 ("As a general rule, the more information that is provided about a particular deposited biological material, the better the examiner will be able to compare the identity and characteristics of the deposited biological material with the prior art.").” MPEP 2163(I) states “The description must be sufficient to permit verification that the deposited biological material is in fact that disclosed. Once the patent issues, the description must be sufficient to aid in the resolution of questions of infringement." Id. at 34,880.)” (Quoting the Deposit of Biological Materials for Patent Purposes, Final Rule, 54 Fed. Reg. 34,864 (August 22, 1989) at 34,880). In the instant application, a full examination cannot be conducted because applicant failed to provide the breeding history for the instantly claimed plant variety. Applicant specifically claims a new soybean plant variety. A plant variety is defined by both its genetics (breeding history) and its traits. In the instant application, applicant has only provided a description of the plant traits as seen in the specification. The instant application is silent as to the breeding history used to produce the claimed plant variety. The criticality of a breeding history in assessing the intellectual property rights of a plant is well recognized in the field of plant breeding. With regard to Plant Patents, MPEP 1605 states that a complete detailed description of a plant includes “the origin or parentage”. Other bodies that grant intellectual property protection for plant varieties require breeding information to evaluate whether protection should be granted to new varieties. A breeding history, including information about parentage and breeding methodology, is part of the requirements of Plant Variety Protection (PVP) applications. That information is used to “determine if development is sufficient to consider the variety new” (See “Applying for a Plant Variety Certificate of Protection” by the USDA reference to Exhibit A, www.ams.usda.gov/services/pvpo/application-help/apply). Additionally, the International Union for the Protection of New Varieties of Plants (UPOV) considers breeding history and methodology part of its evaluation of essentially derived plant varieties (See UPOV EDV Explanatory Notes 14 and 30, www.upov.int/edocs/expndocs/en/upov_exn_edv.pdf). While the USPTO, USDA, and UPOV have different laws governing intellectual property rights, all recognize that a breeding history is an essential part of adequate description of the plant sought to be protected. The breeding history is also necessary to aid in the resolution of patent infringement by providing information necessary to determine whether differences in plants where genetic differences, differences caused by the environment, or differences within the accepted variation within a variety. Historically, the USPTO has considered breeding history information when determining the patentability of a new plant variety. (See Ex Parte C (USPQ 2d 1492 (1992) and Ex Parte McGowen- Board Decision in Application 14/996,093). In both of these cases, there were many differences cited by the applicant when comparing the prior art and the new plant variety. However, because the breeding history was available, these differences were deemed to be obvious and within the natural variation expected in a backcrossing breeding process. Without a breeding history in these cases, a complete comparison with the prior art could not have been possible. Moreover, a specification devoid of a breeding history hampers the public’s ability to resolve infringement analysis with plants already in the prior art as well as plants that have not yet been patented. Because the instant specification lacks the breeding history, the public will not be able to fully resolve questions of infringement. Since the breeding history, including the parents, is not known to the public, the public could only rely on the phenotypes of the claimed plants for assessing potential infringement. As seen above in Ex Parte C and Ex Parte McGowan, a trait table is insufficient to differentiate varieties by itself. It has been long established that intracultivar heterogeneity exists in crop species. HAUN teaches that the assumption that elite cultivars are composed of relatively homogenous genetic pools is false. (Haun et al. The Composition and Origins of Genomic Variation among Individuals of the Soybean Reference Cultivar Williams 82. Plant Physiol. 2010 Nov 29;155(2):645–655, see page 645 Left column). Segregation, recombination, DNA transposition, epigenetic processes, and spontaneous mutations are some of the reasons elite cultivar populations will maintain some degree of plant-to-plant variation. (Haun Page 645 right column and Page 646 left column). In addition to genetic variation, environmental variation may lead to phenotypic variation within a cultivar. (Großkinsky et al. Plant phenomics and the need for physiological phenotyping across scales to narrow the genotype-to-phenotype knowledge gap. J. Exp. Bot. 2015 Sep;66(18):5429-40. Epub 2015 Jul 10, see page 5430 left column 1st full paragraph and right column 2nd full paragraph). In view of this variability, a breeding history is an essential and the least burdensome way to provide genetic information needed at adequate describe a newly developed plant. Thus, an application that does not clearly describe the breeding history does not provide an adequate written description of the invention. To overcome this rejection, applicant must amend the specification/drawing to provide the breeding history used to develop the instant variety or cultivar. When identifying the breeding history, applicant should identify any and all other potential names for all parental lines utilized in the development of the instant variety. For example, if applicant’s breeding history uses proprietary line names, applicant should notate in the specification all other names of the proprietary lines, especially publicly disclosed or patented line information. If the breeding history encompasses a locus conversion or a backcrossing process, applicant should clearly indicate the recurrent parent and the donor plant and specifically name the trait or transgenic event that is being donated to the recurrent parent. If one of the parents is a backcross progeny or locus converted line of a publicly disclosed line, applicant should provide the breeding history of the parent line as well (i.e. grandparents). Applicant is also reminded that they have a duty to disclose information material to patentability. Applicant should also notate the most similar plants which should include any other plants created using similar breeding history (such as siblings of the instant variety). This information can be submitted in an IDS with a notation of the relevancy to the instant application or as information submitted as described in MPEP 724 (e.g., trade secret, proprietary, and Protective Order). Biological Deposit Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Since soybean seed are essential to the claimed invention, the seed must be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If the seed is not so obtainable or available, the requirements of 35 U.S.C. 112 may be satisfied by a deposit thereof. In the instant case the specification does not disclose a repeatable process to obtain the exact same seed in each occurrence, and it is not apparent if such seed is readily available to the public. If a deposit is made under the terms of the Budapest Treaty, then a statement, affidavit or declaration by Applicants, or a statement by an attorney of record over his or her signature and registration number, or someone empowered to make such a statement, stating that the deposit has been accepted and that instant invention will be irrevocably and without restriction released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein. If a deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 CFR 1.801-1.809 and MPEP 2402-2411.05, Applicant may provide assurance of compliance by statement, affidavit or declaration, or by someone empowered to make the same, or by a statement by an attorney of record over his or her signature and registration number showing that: (a) during the pendency of the application, access to the invention will be afforded to the Commissioner upon request; (b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent; (c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the enforceable life of the patent, whichever is longer; (d) the viability of the biological material at the time of deposit will be tested (see 37 CFR 1.807); and (e) the deposit will be replaced if it should ever become inviable. For each deposit made pursuant to these regulations, the specification shall be amended to contain (see 37 CFR 1.809): (1) The accession number for the deposit; (2) The date of the deposit; (3) A description of the deposited biological material sufficient to specifically identify it and to permit examination; and (4) The name and address of the depository. Conclusion No claims are allowed. Claims 1-20, as they read on the elected species of soybean variety EC2141788, appear to be free of the prior art, given the failure of the prior art to teach or reasonably suggest a soybean plant that shares the specific physiological and morphological traits set forth in Table 1 of the specification for soybean variety EC2141788. The closest prior art identified is Lee (US 20200245582, published 8/6/2020), which teaches the soybean variety AR1502197, which differs from the instantly claimed soybean variety in at least the following characteristics: purple flower and yellow hilum (Table 15). Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID R BYRNES whose telephone number is (571)270-3935. The examiner can normally be reached 9:00 - 5:00 M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bratislav Stankovic can be reached at (571) 270-0305. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID R BYRNES/Examiner, Art Unit 1662
Read full office action

Prosecution Timeline

Jan 31, 2025
Application Filed
Aug 04, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12648533
PLANTS AND SEEDS OF CORN VARIETY CV968075
2y 5m to grant Granted Jun 09, 2026
Patent 12642205
LETTUCE VARIETIES 'BIG SHOT' AND 'PIONEER'
2y 9m to grant Granted Jun 02, 2026
Patent 12628758
WHEAT VARIETY 6PUYW59B
2y 4m to grant Granted May 19, 2026
Patent 12604820
CANNABIS VARIETY NWG 4000
3y 0m to grant Granted Apr 21, 2026
Patent 12590316
USE OF beta-1,3-GLUCAN SYNTHASE LIKE 5 IN IMPROVING CLUBROOT DISEASE RESISTANCE AND RELATED PRODUCT DEVELOPMENT IN CRUCIFEROUS CROPS
1y 7m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
99%
With Interview (+22.4%)
2y 5m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 240 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month